1887
  1. Home
  2. Eurosurveillance
  3. Volume 28, Issue 19, 11/May/2023
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

Background

In 2020, Wales experienced some of the highest rates of confirmed COVID-19 cases in Europe. We set up a serosurveillance scheme using residual samples from blood donations to inform the pandemic response in Wales.

Aim

To identify changes in SARS-CoV-2 antibody seroprevalence in Wales by time, demography and location.

Methods

Residual samples from blood donations made in Wales between 29 June 2020 and 20 November 2022 were tested for antibodies to the nucleocapsid antigen (anti-N) of SARS-CoV-2, resulting from natural infection. Donations made between 12 April 2021 and 20 November 2022 were also tested for antibodies to the spike antigen (anti-S) occurring as a result of natural infection and vaccination.

Results

Age-standardised seroprevalence of anti-N antibodies in donors remained stable (4.4–5.5%) until November 2020 before increasing to 16.7% by February 2021. Trends remained steady until November 2021 before increasing, peaking in November 2022 (80.2%). For anti-S, seroprevalence increased from 67.1% to 98.6% between May and September 2021, then remained above 99%. Anti-N seroprevalence was highest in younger donors and in donors living in urban South Wales. In contrast, seroprevalence of anti-S was highest in older donors and was similar across regions. No significant difference was observed by sex. Seroprevalence of anti-N antibodies was higher in Black, Asian and other minority ethnicities (self-reported) compared with White donors, with the converse observed for anti-S antibodies.

Conclusion

We successfully set up long-term serological surveillance of SARS-CoV-2 using residual samples from blood donations, demonstrating variation based on age, ethnicity and location.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.19.2200473
2023-05-11
2024-12-22
/content/10.2807/1560-7917.ES.2023.28.19.2200473
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/19/eurosurv-28-19-4.html?itemId=/content/10.2807/1560-7917.ES.2023.28.19.2200473&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). COVID-19 situation update worldwide, as of week 10, updated 18 March 2021. Stockholm: ECDC. [Accessed: 15 Jan 2021]. Available from: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases
  2. Statista. Incidence of coronavirus (COVID-19) deaths in the EEA and the UK 2021, by country. [Accessed: 15 Jan 2021]. Available from: https://www.statista.com/statistics/1111779/coronavirus-death-rate-europe-by-country
  3. Our World in Data. Coronavirus (COVID-19) cases. [Accessed: 16 Dec 2021]. Available from: https://ourworldindata.org/covid-cases
  4. Tableau Public. Rapid Covid-19 virology. Cardiff: Public Health Wales Health Protection. [Accessed: 25 Oct 2021]. Available from: https://public.tableau.com/app/profile/public.health.wales.health.protection/viz/RapidCOVID-19virology-Public/Headlinesummary
  5. Our World in Data. Coronavirus (COVID-19) vaccinations. [Accessed: 24 Nov 2021]. Available from: https://ourworldindata.org/covid-vaccinations
  6. Osborne K, Gay N, Hesketh L, Morgan-Capner P, Miller E. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol. 2000;29(2):362-8.  https://doi.org/10.1093/ije/29.2.362  PMID: 10817137 
  7. Surenda H, Supargiyono, Ahmad RA, Jusumasari RA, Rahayujati TB, Damayanti SY, et al. Using health facility-based serological surveillance to predict receptive areas at risk of malaria outbreak in elimination areas. BMC Medicine. 2020;18(9).  https://doi.org/10.1186/s12916-019-1482-7  https://doi.org/10.1186/s12916-019-1482-7 
  8. Winter AK, Martinez ME, Cutts FT, Moss WJ, Ferrari MJ, McKee A, et al. Benefits and challenges in using seroprevalence data to inform models for Measles and Rubella elimination. J Infect Dis. 2018;218(3):355-64.  https://doi.org/10.1093/infdis/jiy137  PMID: 29562334 
  9. Arnold BF, Scobie HM, Priest JW, Lammie PJ. Integrated serological surveillance of population immunity and disease transmission. Emerg Infect Dis. 2018;24(7):1188-94.  https://doi.org/10.3201/eid2407.171928  PMID: 29912680 
  10. Antonucci F, Fiore JR, De Feo L, Granato T, Di Stefano M, Faleo G, et al. Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders. Infect Dis (Lond). 2022;54(4):241-6.  https://doi.org/10.1080/23744235.2021.2003856  PMID: 34781812 
  11. StataCorp. 2014. Stata Statistical Software. Release 14. College Station, TX: StataCorp LLC. Available from: https://www.stata.com/
  12. Welsh Government. First Omicron case confirmed in Wales. [Accessed: 4 Oct 2022]. Available from: https://www.gov.wales/first-omicron-case-confirmed-wales
  13. Centers for Disease Control and Prevention (CDC). COVID-19. Atlanta: CDC. [Accessed: 4 Oct 2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/index.html
  14. Tableau Public. Latest vaccination summary. Cardiff: Public Health Wales Health Protection. [Accessed: 23 Jan 2023]. Available from: https://public.tableau.com/app/profile/public.health.wales.health.protection/viz/COVID-19vaccination-Public
  15. Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. MedRXiv. 2020. Available from: https://www.medrxiv.org/content/medrxiv/early/2020/05/18/2020.05.11.20098442.full.pdf https://doi.org/10.1101/2020.05.11.20098442 
  16. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-9.  https://doi.org/10.1016/S0140-6736(20)31304-0  PMID: 32534626 
  17. Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, et al. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. Nat Commun. 2020;11(1):5744.  https://doi.org/10.1038/s41467-020-19481-7  PMID: 33184284 
  18. Yu X, Duan J, Jiang Y, Zhang H. Distinctive trajectories of the COVID-19 epidemic by age and gender: A retrospective modeling of the epidemic in South Korea. Int J Infect Dis. 2020;98(200-205):200-5.  https://doi.org/10.1016/j.ijid.2020.06.101  PMID: 32623081 
  19. Goldstein E, Lipsitch M, Cevik M. On the effect of age on the transmission of SARS-CoV-2 in households, schools and the community. MedRxiv. 2020.  https://doi.org/10.1101/2020.07.19.20157362 
  20. Ward H, Cooke GS, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. Lancet Reg Health Eur. 2021;4(100098):100098.  https://doi.org/10.1016/j.lanepe.2021.100098  PMID: 33969335 
  21. Ward H, Atchison C, Whitaker M, Ainslie KEC, Elliott J, Okell L, et al. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nat Commun. 2021;12(1):905.  https://doi.org/10.1038/s41467-021-21237-w  PMID: 33568663 
  22. Lindsay L, Secrest MH, Rizzo S, Keebler DS, Yang F, Tsai L. Factors associated with COVID-19 viral and antibody test positivity and assessment of test concordance: a retrospective cohort study using electronic health records from the USA. BMJ Open. 2022;11(10):e051707.  https://doi.org/10.1136/bmjopen-2021-051707  PMID: 34598988 
  23. Mathur R, Rentsch CT, Morton CE, Hulme WJ, Schultze A, MacKenna B, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021;397(10286):1711-24.  https://doi.org/10.1016/S0140-6736(21)00634-6  PMID: 33939953 
  24. Coyer L, Boyd A, Schinkel J, Agyemang C, Galenkamp H, Koopman A, et al. SARS-CoV-2 antibody prevalence and determinants of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June-October 2020. MedRxiv. 2021 .  https://doi.org/10.1101/2021.03.08.21252788 
  25. Robertson E, Reeve KS, Niedzwiedz CL, Moore J, Blake M, Green M, et al. Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. Brain Behav Immun. 2021;94:41-50.  https://doi.org/10.1016/j.bbi.2021.03.008  PMID: 33713824 
  26. Momplaisir FM, Kuter BJ, Ghadimi F, Browne S, Nkwihoreze H, Feemster KA, et al. Racial/ethnic differences in COVID-19 vaccine hesitancy among health care workers in 2 large academic hospitals. JAMA Netw Open. 2021;4(8):e2121931.  https://doi.org/10.1001/jamanetworkopen.2021.21931  PMID: 34459907 
  27. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535-44.  https://doi.org/10.1016/S0140-6736(20)31483-5  PMID: 32645347 
  28. Thompson CP, Grayson N, Paton R, Bolton JS, Lourenço J, Penman B, et al. Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020. MedRxiv. 2020 .  https://doi.org/10.1101/2020.04.13.20060467 
  29. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063.  https://doi.org/10.1126/science.abf4063  PMID: 33408181 
  30. Dehgani-Mobaraki P, Zaidi AK, Porreca A, Floridi A, Floridi E. Neutralizing antibody responses 10 months after mild and moderately-severe SARS-CoV-2 infection. MedRxiv. 2021 .  https://doi.org/10.1101/2021.02.22.21252225 
  31. National Institutes of Health (NIH). Lasting immunity found after recovery from COVID-19. Bethesda: NIH; 2021. Available from: https://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19
  32. Centers for Disease Control and Prevention (CDC). Antibodies and COVID-19. Atlanta; CDC. [Accessed: 4 May 2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/your-health/about-covid-19/antibodies.html
  33. Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinicalMedicine. 2021;36(100902):100902.  https://doi.org/10.1016/j.eclinm.2021.100902  PMID: 34056568 
  34. Fischer B, Knabbe C, Vollmer T. Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response. PLoS One. 2022;17(12):e0279195.  https://doi.org/10.1371/journal.pone.0279195  PMID: 36525449 
  35. Siller A, Seekircher L, Wachter GA, Astl M, Tschiderer L, Pfeifer B, et al. Seroprevalence, waning and correlated of anti-SARS-CoV-2 IgG antibodies in Tyrol, Austria: Large-scale study of 35,193 blood donors conducted between June 2020 and September 2021. Viruses. 2022;14(3):568.  https://doi.org/10.3390/v14030568  PMID: 35336975 
  36. Erikstrup C, Laksafoss AD, Gladov J, Kaspersen KA, Mikkelsen S, Hindhede L, et al. Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. Lancet Reg Health Eur. 2022;21(100479):100479.  https://doi.org/10.1016/j.lanepe.2022.100479  PMID: 35959415 
  37. StatsWales. Population estimates by local authority and year. 2021. [Accessed: 25 Jul 2021]. Available from: https://statswales.gov.wales/Catalogue/Population-and-Migration/Population/Estimates/Local-Authority/populationestimates-by-localauthority-year
  38. StatsWales. Ethnicity by area and ethnic group. 2021. [Accessed: 25 Jul 2021]. Available from: https://statswales.gov.wales/Catalogue/Equality-and-Diversity/Ethnicity/ethnicity-by-area-ethnicgroup
Serosurveillance of SARS-CoV-2 in Welsh Blood Donors: Establishment of the surveillance system and results up to November 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Sophie+Harker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Harker Sophie</a>, <a href="/search?value1=Si%C3%A2n+Elizabeth+James&option1=author&noRedirect=true" class="nonDisambigAuthorLink">James Siân Elizabeth</a>, <a href="/search?value1=James+Murphy&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Murphy James</a>, <a href="/search?value1=Ben+Davies&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Davies Ben</a>, <a href="/search?value1=Catherine+Moore&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Moore Catherine</a>, <a href="/search?value1=Brian+P+Tennant&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Tennant Brian P</a>, <a href="/search?value1=John+Geen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Geen John</a>, <a href="/search?value1=Daniel+Thomas&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Thomas Daniel</a></span>. Serosurveillance of SARS-CoV-2 in Welsh Blood Donors: Establishment of the surveillance system and results up to November 2022. <a href="/content/ecdc">Euro Surveill.</a> 2023;28(19):pii=2200473. <a href="https://doi.org/10.2807/1560-7917.ES.2023.28.19.2200473" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2023.28.19.2200473</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 09 Jun 2022;&nbsp;&nbsp; <span class="generated">Accepted</span>: 10 Feb 2023 </span> </p>
/content/10.2807/1560-7917.ES.2023.28.19.2200473
/content/10.2807/1560-7917.ES.2023.28.19.2200473
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error